London, 26 August 2020. With children in England back to school next week (and already back in other UK nations), and with government advice shifting towards encouraging more children to wear facemasks, Air Queen UK is today making available the new “AirBon” facemask, specially sized for children.
The World Health Organisation recommends that children aged twelve and over should wear a mask under the same conditions as adults, especially where they cannot guarantee at least a one metre social distance. This recommendation has now been adopted by the UK government with respect to schools, and in response Air Queen UK is now supplying the specially sized AirBon facemasks for children.
TopTec, the South Korean manufacturer of the AirBons, recognised the challenges faced by parents seeking to adequately protect their children, in particular that many children are using masks sized for adults, compromising the quality of the fit; or using 3-ply masks with vastly inferior comfort and filtration efficiency. TopTec took their FDA-approved surgical respirator with nano-filter technology (the “Air Queen”) and re-designed it to fit the smaller faces of children.
The new AirBon masks deploy the same uncompromising filter and manufacturing technology as in the popular adult-sized Air Queen masks. Air Queen masks are N95 equivalent (FDA 510k approved) surgical respirators designed and approved for use by operating room personnel during surgical procedures, protecting both the wearer and others.
While the AirBon masks are clearly not designed for use in operating theatres, they use identical filtration and ergonomic face-fit features as the larger Air Queen masks. Parents can therefore take some comfort that their children are using the same protective technology to help prevent their kids from contact with Covid-19 and other harmful contaminants.
As schools re-open children are beginning to interact on a more regular basis and to help parents navigate the potential risks of their children contracting or spreading Covid-19, the AirBon is now available from www.air-queen.co.uk priced from £2 per mask.
More details about both the AirBon and Air Queen facemasks can be found at www.air-queen.co.uk.
Brains Bioceutical Corp (“BRAINS” or the “Company”)(Vancouver, Canada), a global leader in pharmaceutical, wellness and veterinary cannabidiol (CBD) based Active Pharmaceutical Ingredient (API) production, is proud to announce its landmark accomplishment to bring Brazil’s first registered medical cannabis product under the new regulations that ANVISA put in place in December of 2019, Brains EU-GMP CBD API to the Brazilian market.
“Our partners in Brazil are a global leader in pharmaceutical production and clinical trials. I’m very proud of this historic moment, wherein we have combined our strengths to create the first registered product under the new regime. The standard we have set for the purity of our CBD is second to none. The team of world-renowned scientists and executives at Brains, continue to achieve landmark milestones with a relentless pursuit of historic firsts in the CBD industry. We look forward to monetizing and capitalizing on the resulting market opportunities that this launch will propel us towards. We now have registered CBD product in the epicenter of the European continent within the UK, and supply the CBD material to our South American partner for achieving the first registered cannabis product under the new ANVIA regulations in Brazil.” said Rick Brar, Chairman and CEO of Brains Bioceutical Corp.
Brains South American partner is a leader in the global pharmaceutical industry. Producing approximately 11.5 billion therapeutic doses per year, and has more than 4,200 employees. The company has one of the largest portfolios of generic drugs in Brazil, and supplies both South American and global markets. Since the recent announcement in December 2019, this is the first registered cannabis product under the special category created by ANVISA. We will be able to export Brains EU-GMP CBD API from the UK for our partner in Brazil to formulate their products to be sold in pharmacies and distributors in Brazil and potentially expand that to the rest of South America as the marketplace expands. All of our partners formulations adhere to the highest quality for manufacturing and testing with a view to making it the safest product available in the region. Under the terms of the agreement, Brains will provide its EU-GMP, CBD API to be used in the registered cannabis products.
“Now more than ever, it is important that patients have access to products that do not compromise on safety and quality. We believe that these products are bringing forward the highest quality product into South America. The Brains industry leading regulatory team was able to introduce the first cannabinoid based specials products in the UK and the first to supply our EU-GMP API ingredient to our partner in Brazil. Brains CBD is one of the few natural, plant-based API ingredients available anywhere on the planet. This team will successfully lead Brains to another first later this year, when we spearhead the reshaping of the CBD industry in the UK by taking the same approach for our Novel Foods application,” added Gurdeep Bains, President of Brains.
Since 2014, Brains subsidiary, BSPG Laboratories, has been a leader in clinical stage, natural source, cannabinoid manufacturing located in Sandwich, Kent, United Kingdom. Brains presently has Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval to manufacture an approved pharmaceutical grade ingredient (API) for the global pharmaceutical industry. Having shipped over 100 kilos to Brazil over the past year, Brains has been providing patients in Brazil with reliable access for over 2 years.
About Brains Bioceutical Corp Brains Bioceutical Corp is a leader in GMP – certified production of naturally sourced active pharmaceutical ingredients (APIs) for the pharmaceutical and nutraceutical industries. Brains Bioceutical is one of the only natural plant-based cannabinoid active pharmaceutical ingredient (API) manufacturers in commercial production today and is involved in academic and clinical trials across the globe.
Brains Bioceutical Corp. Senior Management Team is made up of a rare hybrid of pharmaceutical and consumer goods executives-having held C-suite and other senior positions with companies such as GW Pharma, Merck, Seattle Seahawks, Golden State Warriors, Danone, Earthbound Farms, International Herbs, Cascadia Specialties and The Royal British Navy. This experience allows Brains to execute at a hyper-efficient level in the pharma and wellness categories.
Brains’ wholly owned subsidiary in the UK, BSPG Laboratories is one of only nine companies that has the commercial capability and EudraGMDP certification to produce CBD API, and is only one of four worldwide to source a natural plant based cannabidiol. Brains is currently manufacturing a line of phytocannabinoid THC-free CBD API products.
MHRA Registered API: Inspected and Registered with the MHRA (Medicines and Healthcare Products Regulatory Agency).
CAUTIONARY STATEMENT: This news release contains forward looking statements or forward-looking information (“forward-looking statements”) within the meaning of securities laws. Often, but not always, forward looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. All statements, other than statements of historical fact, in this news release are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance are not statements of historical fact and may be forward-looking statements. Risks, uncertainties and other factors involved with forward-looking statements could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements in this news release are reasonable, there can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
Caneaze.com has launched an e-commerce platform to bring CBD wellness brands that undertake extensive research into the effectiveness of their products to the UK market. Caneaze specialises in retailing high-end CBD products that contain effective quantities of the cannabis derived extract for use as a natural medicinal remedy. Caneaze started in February of 2019 in London.
WHAT DOES CANEAZE AIM TO DO?
Caneaze.com aims to become a leader in the growing UK CBD wellness market by providing customers with a variety of CBD products that have proven their effectiveness and passed the retailers stringent testing procedure, while also providing clear information backed by medical experts, such as scientific studies or clinical trials. The Platform houses many top US CBD brands such as Papa And Barkley and Medterra. The platform also provides information on areas that are proving confusing to consumers, like dosages and the CBD to THC ratio to guide customers through CBD treatments and products.
WHAT SORT OF PRODUCTS ARE AVAILABLE?
The products sold through caneaze.com specialise in; pain relief, sleep aid and maintaining general wellness. Further to this, the products sold by the retailer are all subject to a testing process to ensure the quantities of CBD stated on the label are correct for that batch and the product is completely free from pesticides and heavy metals. The retailer only works with suppliers that grow their own Hemp or have long standing relationships with the growers in order to ensure the consistent quality of the cannabis derived extract.
WHAT OTHER CONTENT IS THERE?
The retailer is also focused on creating user friendly content enabling UK consumers to learn about using CBD medicinally and covering the growth, development and innovation of products within the CBD wellness market. The retailer hosts expert guest bloggers and contributors who create content for specific niches like using CBD in personal care products for women in menopause, and using CBD to treat chronic pain conditions like Fibromyalgia.
I AM NEW TO CBD – ARE THERE PRODUCTS SUITABLE FOR ME?
The products sold through the platform vary in form, from tinctures to edible products and skin creams. Caneaze provides clear instructions to guide you through applying or consuming these products. Furthermore, on the platform there is an oppurtunity to become a member of the Caneaze family which includes receiving regular updates on new products along with content and wellness tips. Caneaze offers customers monthly reports and updates relating to using CBD effectively. Join at https:// caneaze.com/account/login